A flood in Ohio and a trip to the loan market do not sound like parts of the same story, but today they arrived five minutes apart. Integra LifeSciences Holdings Corporation (NASDAQ: IART), a medical technology company based in Princeton, New Jersey, told investors it wants to borrow $600 million to replace older debt. Shortly afterward, it said this year’s sales and profit will come in lower than it had previously forecast. Integra makes surgical and regenerative products used in neurosurgery and tissue reconstruction, and sells them to hospitals around the world.
Start with the borrowing. The company is proposing what lenders call a Senior Secured Term Loan B, which would run for seven years. In plain terms, this is a large loan sold to institutional investors, not held by a single bank. “Senior secured” means the lenders are backed by company assets and stand near the front of the line for repayment. Integra says the money, combined with other sources of financing it did not describe, would be used to pay off certain existing debt and cover the fees involved. Chief Financial Officer Lea Knight described the goal as refinancing existing debt and pushing out maturities while keeping financial flexibility.
The release does not say which debts will be retired, so it helps to look at what the company owes. According to its most recent quarterly filing, Integra had roughly $1.8 billion outstanding under its main bank credit facility at the end of June 2026, split between a term loan and a revolving credit line. Much of the revolving balance dates to 2025, when the company used it to repay $575 million of maturing convertible notes. Borrowings under that revolving line come due in March 2028. That date is still about a year and a half away, but companies generally prefer to refinance well before a deadline. A $600 million loan would cover only part of the total, which explains the reference to other financing.
The second announcement explains why the timing is awkward. In July 2026, flooding damaged part of Integra’s manufacturing site in Cincinnati, along with equipment and inventory. The plant makes several products in the company’s surgical technologies business. Integra has been drawing on existing stock and alternate suppliers, and it says it now has a clearer view of how long the recovery will take. The disruption is expected to weigh more heavily on the fourth quarter than it did on the third, and the site is not expected to return to full production until the second quarter of 2027.
As a result, the company now expects 2026 revenue of between $1.634 billion and $1.654 billion, which means the top of the new range is the bottom of the old one. Adjusted earnings per share are forecast at between $2.30 and $2.40, a dime lower at both ends. The company noted that the revision also reflects updated assumptions about the rest of the business, not only the flood. One figure offers some reassurance: Integra expects to generate between roughly $190 million and $200 million in operating cash flow this year, which matters for a company that says it wants to reduce debt.
Insurance is the big unknown. Integra carries both property and business interruption coverage on the Cincinnati facility and expects recoveries to offset a substantial portion of the earnings impact. It has not put a dollar figure on that, and it is still working with its insurer to document the losses. Until a number emerges, investors cannot tell how much of the shortfall is temporary.
The loan carries its own open questions. Integra cautioned that there is no assurance the financing will be completed, and that its final size, terms and pricing are not settled. Lenders will be setting an interest rate just as the company trims its outlook, and a higher rate would mean more cash going to interest and less to paying down what it owes. Two things should bring clarity in the coming weeks: the final terms of the loan, and the full third quarter report, which Integra plans to deliver on a conference call later in October.
